Olgu Sunumu
Yıl 2020,
Cilt: 21 Sayı: 2, 163 - 166, 31.08.2020
Öz
Guillain-Barré syndrome (GBS), an acute demyelinating inflammatory poliradiculopathy, is characterised by rapidly progressive, symmetrical, ascending weakness and areflexia. The disease usually occurs after 1-3 weeks of infection, vaccinations, trauma, surgical interventions and immunosuppression. Facial diplegia and paraesthesia which is a rare GBS variant has no weakness whereas, GBS is present with weakness which usually begins from lower extremities. In this article, three cases were presented to emphasise the importance of GBS in patients with facial diplegia.
Anahtar Kelimeler
Kaynakça
- 1. Visser LH, van der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996; 47: 668-73.
- 2. Akarsu EO, Yalçın D, Sürmeli R, Demir A, Sünter G, Diler Y. A Rare Variant of Guillain-Barre Syndrome: Facial Diplegia Paresthesia. Turk J Neurol 2015; 21: 171-4.
- 3. Cros D, Triggs WJ. Guillain Barre syndrome: clinical neurophysiologic studies. Rev Neurol (Paris) 1996; 152: 339-43.
- 4. Brannagan TH 3rd. Intravenous gammaglobulin for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002; 59: S33-40.
- 5. Bradley Walter G. Neurology in Clinical Practice Guillain Barre Syndrome 2012; S2288-96.
Yıl 2020,
Cilt: 21 Sayı: 2, 163 - 166, 31.08.2020
Öz
Kaynakça
- 1. Visser LH, van der Meche FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996; 47: 668-73.
- 2. Akarsu EO, Yalçın D, Sürmeli R, Demir A, Sünter G, Diler Y. A Rare Variant of Guillain-Barre Syndrome: Facial Diplegia Paresthesia. Turk J Neurol 2015; 21: 171-4.
- 3. Cros D, Triggs WJ. Guillain Barre syndrome: clinical neurophysiologic studies. Rev Neurol (Paris) 1996; 152: 339-43.
- 4. Brannagan TH 3rd. Intravenous gammaglobulin for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002; 59: S33-40.
- 5. Bradley Walter G. Neurology in Clinical Practice Guillain Barre Syndrome 2012; S2288-96.
Toplam 5 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Nöroloji ve Nöromüsküler Hastalıklar |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Yayımlanma Tarihi | 31 Ağustos 2020 |
| Yayımlandığı Sayı | Yıl 2020 Cilt: 21 Sayı: 2 |